01/07/2021 | Press release | Distributed by Public on 01/07/2021 15:07
Redwood City, California, and Hilden, Germany, Jan 7, 2021- QIAGEN announced today the exclusive rights to license and distribute the COSMIC Database for commercial use from the Wellcome Sanger Institute. The COSMIC Databasejoins QIAGEN's leading portfolioof hereditary and somatic genetic mutation interpretation software and databases that includes IPA, HGMD, QCI Interpret, QCI Precision Insightsand OmicSoft Oncoland. The extended portfolio now provides researchers and clinicians with options to access manually curated somatic mutation information as standalone databases, as an integrated Knowledge Base, through automated analysis software or as an interpretation service based on their unique needs and preferences.
Under the multi-year agreement, QIAGEN will leverage its experienced software sales team and global customer network to grow the adoption and utilization of the COSMIC Database. First line of support for all commercial enquiries will be managed through QIAGENs' existing global support channel that currently assists over 90,000 users of existing QIAGEN software.
'The COSMIC Database is one of the premier somatic mutation databases. We are honored that the Wellcome Sanger Institute has entrusted QIAGEN to be its first commercial software partner and to grow its flagship database,' said Jonathan Sheldon, Senior Vice President of QIAGEN Digital Insights. 'Our common focus on building and providing interpretation Knowledge Bases, combined with our respective leadership positions in delivering interpretation information makes this a natural partnership. Both Sanger and QIAGEN share the same philosophy to ensuring high quality knowledge access through carefully curated, compiled and standardized information. Our mutual customers can now benefit from over 30 years of QIAGEN Digital Insights global experience delivering and supporting industry leading products.'
The COSMIC Database is used by over 20,000 researchers, bioinformaticians and clinicians across the world who are interpreting cancer variants and understanding how these gene mutations drive cancer. The Database provides a single point of access to high quality mutation information carefully curated by expert postdoctoral scientists from over 27,000 scientific and clinical reports, and 500 independent cancer genome studies and international consortia, covering more than 1,500 cancer types at high resolution.
For academic research, access to the COSMIC Database is available at no charge from the Sanger Institute. For commercial use, users pay a license fee to access the Database, which is available for download, annotation and integration. COSMIC will remain a not-for-profit organization, with commercial profits invested in its growth and the Sanger Institute's scientific programs.
'COSMIC is a huge database underpinning cancer precision medicine and we're curating more information across genetic oncology than ever before,' said Dr Simon Forbes, Director of COSMIC at the Wellcome Sanger Institute. 'Partnering with QIAGEN who have enormous expertise in global bioinformatic markets, we will sustain and grow this resource for everyone's benefit. Together, we're making huge genomic data increasingly valuable and accessible to the people curing cancer, whether they be in industry, academia or healthcare, ensuring precision medicine is brought to maturity.'
'We are delighted to partner with QIAGEN who are world leaders in the commercial distribution of globally significant data resources like COSMIC,' said Dr Adrian Ibrahim, Head of Technology Transfer and Business Development at the Wellcome Sanger Institute. 'Through this partnership we will further pursue our vision to enable the global cancer research, discovery and development community with the gold standard resource that COSMIC represents, whilst reaffirming our commitment to maintain free access to not-for-profit academic users.'
COSMIC - the Catalogue of Somatic Mutations In Cancer - is an expert-curated database describing the wide variety of genetic variations associated with all forms of human cancer. A key resource underpinning cancer genetic research, COSMIC provides large high-quality datasets, methods and graphics to scrutinise the genetics causing this disease, giving insights to pharmaceutical design and patient therapies. Built within the world-leading Sanger Institute (UK) to support global research, millions of mutations across thousands of diseases can be explored at https://cancer.sanger.ac.uk
About the Wellcome Sanger Institute
The Wellcome Sanger Institute is a world leading genomics research centre. We undertake large-scale research that forms the foundations of knowledge in biology and medicine. We are open and collaborative; our data, results, tools and technologies are shared across the globe to advance science. Our ambition is vast - we take on projects that are not possible anywhere else. We use the power of genome sequencing to understand and harness the information in DNA. Funded by Wellcome (one of the biggest charitable healthcare foundations in the world) we have the freedom and support to push the boundaries of genomics. Our findings are used to improve health and to understand life on Earth. Find out more at www.sanger.ac.ukor follow us on Twitter, Facebook, LinkedInand on our Blog.
About QIAGEN Digital Insights
QIAGEN Digital Insights is a Business Unit with QIAGEN N.V., a Netherlands-based holding company and a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. QIAGEN Digital Insights delivers expert curated genomic and clinical knowledge, software and services for scientists and clinicians to improve insights, accelerate decision and deliver better outcomes. The QIAGEN Knowledge Base is the most comprehensive source of publicly available curated omics data to support research, clinical trials and clinical testing labs. Developed and acquired through acquisitions of Ingenuity LLC, CLC LLC, OmicSoft LLC, BioBase and N-of-One, the Knowledge Base includes 40+ databases, 33,000+ diseases and over 20 million findings with over 5,000 findings added daily. Today 35,000 public citations reference Digital Insights products, and over 1,600,000 patient samples have been analyzed.
Further information can be found at https://digitalinsights.qiagen.com
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, including those products used in the response to the COVID-19 pandemic, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, including the breadth and duration of the COVID-19 pandemic and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading 'Risk Factors' contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.